SeaX Ventures Links US Heart-Patch Startup Skribe to SE Asia Clinics

SeaX Ventures has recruited more than 100 patients in Southeast Asia for clinical studies run by Skribe Medical, a US medical technology startup whose wearable patch monitors heart damage in cancer patients.

Skribe announced the milestone on Wednesday. The Bangkok-connected venture firm — headquartered in San Francisco with an office in Bangkok — connected the startup with hospital partners across the region and managed patient recruitment for its research program.

The deal puts SeaX's investment thesis to work: pairing US deep-tech founders with Southeast Asia's hospital networks to build clinical evidence faster.

What does Skribe's technology actually do?

Skribe is developing a wearable patch, called Aurora, paired with AI software. Together they estimate left ventricular ejection fraction — the share of blood the heart's main pumping chamber pushes out with each beat.

Oncologists rely on that measure to track heart damage caused by some cancer treatments. The patch fits into routine oncology visits today, with home monitoring as the longer-term goal.

The evidence base is growing. More than 800 patients have enrolled in Skribe's NOECHO study across 10 US sites and one site in Southeast Asia.

Who funded it, and how much?

SeaX led Skribe's $1.65 million pre-seed round. GoAhead Ventures and Marin Sonoma Impact Ventures also participated. The capital has funded both technology development and the clinical research now running across two continents.

SeaX invests from pre-seed through growth-equity stages and has worked with more than 500 listed companies, multinationals, and major family businesses in Southeast Asia.

Kid Parchariyanon, managing partner of SeaX Ventures, said the Skribe work demonstrates the firm's model in practice.

"For deep-tech founders, access to capital is only part of the challenge. They also need the right clinical partners to build evidence and a credible path to market," he said.

Why does this matter for cross-border medtech?

The Skribe arrangement shows how a mid-sized fund can add value beyond capital. SeaX supplied the clinical partners and patient pipeline that a pre-seed hardware startup would struggle to secure alone in a foreign market.

It is not the firm's only cross-border play. In May, SeaX backed Melazyme, which raised a $2 million seed round to scale a precision fermentation platform.

For Skribe, the Southeast Asia site extends the NOECHO study beyond its 10 US locations — and moves the company closer to a commercial pathway built on evidence from multiple markets.